Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.

CONCLUSION: These findings demonstrate sustained daily symptom and HRQoL benefits of FF/UMEC/VI versus BUD/FOR. The inclusion of the CAT may provide data that are readily generalizable to everyday clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov number: NCT02345161. FUNDING: GSK. PMID: 29313286 [PubMed - as supplied by publisher]
Source: Adv Data - Category: Epidemiology Authors: Tags: Adv Ther Source Type: research